Work

Identification of endometrial cancer methylation features using a combined methylation analysis method

Year: 2016
Type: article
Abstract: Introduction: DNA methylation is a stable epigenetic mark that is frequently altered in tumors.DNA methylation marks are attractive biomarkers for disease states given the stability of DNA methylation in living cells and in biologic specimens.Widespread accumulation of methylation in regulatory elements in some cancers (termed the CpG island methylator phenotype, CIMP) can play an important role in tumorigenesis.High resolution assessment of CIMP for the entire genome, however, remains cost prohibitive and requires quantities of DNA that are not available for many tissue samples of interest.Genome-wide scans of methylation have been undertaken for large numbers of tumors, and higher resolution analyses have been performed for a limited number of cancer specimens.Yet methods for analyzing these large datasets and integrating findings from different studies have not been fully developed.An approach was developed to profile CIMP by combining the strengths of two different methylome profiling techniques.Methods: Methylomes for 76 primary endometrial cancer and 12 normal endometrial samples were generated using methylated fragment capture and second generation sequencing (MethylCap-seq).Publically available data from The Cancer Genome Atlas (TCGA) for 203 endometrial cancers, analyzed using the Infinium HumanMethylation 450 beadchip, were compared to the MethylCap-seq data.A MethylCap-seq quality control module was iii developed to exclude sequencing samples with poor-quality methylation data from analysis.Additional MethylCap-seq datasets were also used to develop and validate the quality control module. Results: Analysis of total methylation in promoter CpG islands (CGIs)identified a subset of tumors with a methylator phenotype.I developed a 13region methylation signature associated with a "hypermethylator state" using a training set of five highly methylated and eight lowly methylated tumors.The signature was validated using data from TCGA.High signature methylation score was associated with mismatch repair deficiency, high mutation rate, and low somatic copy number alteration in TCGA test set.In addition, the methylation signature distinguished >90% of endometrioid endometrial tumors from normal controls in the test set.Furthermore, classification of tumors by signature methylation score proved highly robust, showing good agreement with previously published methylation clusters for the test set as well as consistent ranking of tumors across alternative signatures.Conclusion: I identified a methylation signature for a "hypermethylator phenotype" in endometrial cancer and developed methods that could prove useful for identifying extreme methylation phenotypes in other cancers.
Author: Trimarchi, Michael Paul, Trimarchi
Language: English
Open Access status: green
OpenAlex ID: W7010453935
FWCI:
Cites: 101
Cited by:
Related to: 10